A recent study using optical coherence tomography angiography has shown progressive capillary loss in both the optic nerve head and the macula over the anti-VEGF treatment course of 12 months, suggesting the role of IVI therapy in glaucoma progression32. This evidence concerns the gene VEGFA and glaucoma.